ZyVersa Therapeutics, Inc. has officially requested the U.S. Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-3 effective as of September 9, 2024, at 5:00 p.m. Eastern Time. The request, made under Rule 461 of the Securities Act of 1933, was submitted through a correspondence filed via EDGAR. ZyVersa Therapeutics, located at 2200 N. Commerce Parkway, Suite 208, Weston, Florida, has indicated that the effective date and time are subject to change if the company provides prior notification to the SEC. The company's Chief Executive Officer, Stephen C. Glover, signed the request, and any inquiries regarding this matter are to be directed to Faith L. Charles of Thompson Hine LLP, the company's outside counsel.

ZyVersa Therapeutics, Inc. has officially requested the U.S. Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-3 effective as of September 9, 2024, at 5:00 p.m. Eastern Time. The request, made under Rule 461 of the Securities Act of 1933, was submitted through a correspondence filed via EDGAR. ZyVersa Therapeutics, located at 2200 N. Commerce Parkway, Suite 208, Weston, Florida, has indicated that the effective date and time are subject to change if the company provides prior notification to the SEC. The company's Chief Executive Officer, Stephen C. Glover, signed the request, and any inquiries regarding this matter are to be directed to Faith L. Charles of Thompson Hine LLP, the company's outside counsel.